Company intelligence / Profile preview

Immagene

Netherlands

Ownership: Private
Development stage: Other

Overview

Immagene is a newly launched Dutch biotech developing next-generation precision immuno-oncology therapeutics; publicly available information suggests the company is in early, likely preclinical, stages with no disclosed clinical results yet.[7]

Therapeutic areas: Oncology
Industry: Biotech

Partnerships

Oncode Institute (innovation/launch support collaboration inferred from launch announcement context)[7]

Beyond the preview

Go deeper on Immagene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immagene.

Explore the full profile